© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 15, 2014
A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.
Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.
April 13, 2014
Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.
Results from the NEED study show combination treatment with peginterferon alpha-2a and either adefovir or entecavir does not increase HBeAg seroconversion rate compared to monotherapy alone in patients with hepatitis B.